Session Details
[P3]Poster Presentaion
Fri. Mar 6, 2026 11:05 AM - 12:05 PM JST
Fri. Mar 6, 2026 2:05 AM - 3:05 AM UTC
Fri. Mar 6, 2026 2:05 AM - 3:05 AM UTC
Poster Session(1st Floor)
[P3-01]Efficient Generation of Monoclonal Antibodies to Small Molecules by Combining Optimal Antigen Design, Single-Cell Method, and Cell-Free Antibody Expression
*Shoji Ohuchi1, Tomoe Yamauchi1, Koya UEKUSA2, Taiga SUZUKI2, Tomiko Yamada1, KC Kao1, Yoshiaki MASAKI2, Koji Seio2 (1. iBody Inc., 2. Science Tokyo)
[P3-02]Method development and application of a generic monkey ADA assay in the early development stage of antibody drugs
*Shio Maruyama1, Arisa Inoue1, Hiroyuki Shimizu1 (1. Tanabe Pharma Corporation)
[P3-03]Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity
*Luca Genovesi1, Mark Watson1, Gwenael Pottiez1 (1. CellCarta)
[P3-04]Quantitative analysis of D/L-Ser and D/L-Pro in serum from Alzheimer's disease patients by stable isotope-coded derivatization in using the highly sensitive labeling reagent D-FDLDA
*Yasunari Yamada1, Tsunehisa Hirose1, Motoshi Shimotsuma1, Akari Ikeda2, Takahiro Kawase3, Ai Tsuji4, Shozo Tomonaga5, Takefumi Kuranaga6, Hideaki Kakeya6, Makoto Ozaki1 (1. Nacalai Tesque Inc., Dept. of Research and Development, 2. SI Inovation Center, Taiyo Nippon Sanso Co., 3. Kyoto Institute of Nutrition & Pathology, Inc., 4. Dept. of Regional Creation, Prefectual Univ. of Hiroshima, 5. Division of Applied Biosciences, Graduate School of Agriculture, Kyoto Univ., 6. Dept. of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto Univ.)
[P3-05]Development of an LC—FAIMS—MS/MS Analytical Method and Plasma Quantification Technique for an Cyclic Peptide Calcitonin Analogueː Toward the Establishment of Anti-Doping Testing for Cyclic Peptides in Racehorses
*Kohei Ohnuma1, Minori Fukazawa1, Taiga Uchida1, Yohei Minamijima1, Michiko Bannai1, Mariko Shibuya1, Masayuki Yamada1, Misato Hirano-Kodaira1 (1. Drug Analysis Department, Laboratory of Racing Chemistry)
[P3-06]Bioanalytical Strategy for Peptide Immunogenicity
*Chris Hammond1, Zhenqiang Li1, Hema Desai1 (1. Syneos Health)
[P3-07]Study of factors influencing performance of in vitro immunogenicity assay
*Michihiko Aoyama1, Takuo Suzuki1, Minoru Tada1, Akiko Ishii-Watabe1 (1. National Institute of Health Sciences)
[P3-08]Development of an Integrated Platform for Biomarker Discovery Through Extracellular Vesicle Isolation, Multi-Omics Profiling, and ddPCR-Based Quantification
*Sayaka Sato1, Ran Gu1, Naoya Kubo1, Ibuki Tsuchida1, Yuta Shimizu1 (1. H.U. Group Research Institute G.K.)
[P3-09]Development of analytical methods for drug-to-antibody ratio, drug load distribution and site-specific drug-conjugation rate of ADC in human plasma
*Noritaka Hashii1, Chihiro Obata1, Hiroki Oh2, Atsushi Yonezawa2, Akiko Ishii-Watabe1 (1. National Institute of Health Sciences, 2. Keio University)
[P3-10]Development and performance evaluation of a high-throughput extracellular vesicle isolation method for biomarker discovery
*Ryosuke Otake1, Mizuki Kajimura1, Kana Warashina1, Ran Gu1, Yuta Shimizu1 (1. H.U. Group Research Institute G.K.)
[P3-11]Optimization and comparison of electrochemiluminescence immunoassay and Gyrolab platforms for the quantification of E6011 in monkey serum
*Kei Nabeshima1, Haruna Ono1, Tomoko Kojima1, Yuji Mano2,3 (1. DMPK&Bioanalysis Unit, Sunplanet Co., Ltd., 2. Global Drug Metabolism and Pharmacokinetics, Eisai Co., Ltd., 3. Laboratory of Genomics-based Drug Discovery, Faculty of Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba)
[P3-12]Imaging antibody drug internalization using Quanticell
*Hironori Ishii1, Masaru Takahashi1, Misato Jinno2, Akinobu Hamada2, Tetsuya Ooishi1 (1. Precision Business Management Group, KONICA MINOLTA, INC. , 2. Division of Molecular Pharmacology, National Cancer Center Research Institute)
[P3-13]Development of two type of LC/MS based bioanalytical methods for 3003pep in plasma
*Kazuki Yamamoto1, Naoko Arashida1, Kazutaka shimbo1, Akira Nakayama1, Ryoya Goda2 (1. AJINOMOTO CO., INC., 2. Future Peak)
[P3-14]Survey on toxicokinetics guidance (ICH-S3A guideline): Current landscape and challenges faced by pharmaceutical companies
*Takuya Kuno1, Ryota Higuchi1, Tomoyuki Kishida1, Yuko Itsuji1, Mami Kamada1, Takaaki Tanabe1, Yuki Inoue1, Mutsumi Suzuki1 (1. Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association)
[P3-15]Multi-laboratory evaluation study of LC-MS based bioanalytical method for BT1718 in plasma
*Rika Ishikawa1, Koichi Shiga2, Kazuki Yamamoto3, Koichiro Hotta4, Masayoshi Mizuochi5, Mitsuhiko Kawabata6, Takuma Shigeyama7, Hitomi Shimoda8, Hisashi Fujita9, Norihiko Iwazaki10, Ryo Yamato11, Takashi Misawa1, Yosuke Demizu1, Yoshiro Saito1, Ruri Kikura-Hanajiri1, Kosuke Saito1 (1. National Institute of Health Sciences, 2. Axcelead Drug Discovery Partners, Inc., 3. Ajinomoto. Co., Inc., 4. Eisai Co., Ltd., 5. CMIC Pharma Science Co., Ltd., 6. Shin Nippon Biomedical Laboratories, Ltd., 7. Sumika Chemical Analysis Service, Ltd., 8. Daiichi Sankyo Co., Ltd., 9. Takeda Pharmaceutical Company Limited, 10. Mitsubishi Tanabe Pharma Corporation, 11. Mediford Corporation)
[P3-16]Introduction of Automation Technology for Bottom-Up LC/MS/MS Quantification of Antibody-Drug Conjugates, ADC
*Akihiro Ito1, Suguru Fukuda1, Shiori Miyawaki1 (1. Shin Nippon Biomedical Laboratories, Ltd. Drug Safety Research Laboratories)
[P3-17]Development of a Comprehensive Quantification Method for Antibody-Drug Conjugates Using a Single LC/MS Platform
*Yoshiharu Hayashi1, Eriko Matsui1, Aki Koyama1 (1. CMIC Pharma Science Co., Ltd.)
[P3-18]Advancing ADC Drug Discovery with LC-MS/MS: Comprehensive Quantitation of unconjugated payload, antibody-conjugated payload, conjugated antibody and total antibody
yukako yamamoto1, yuki yoshimura1, *Seiichi Matsui1, kenichi watanabe1, jun tadano1 (1. Bioanalysis Group, Sumika Chemical Analysis Service,Ltd.)